GPCR
Structure Therapeutics Inc - ADR

2,025
Mkt Cap
$4.45B
Volume
518,340.00
52W High
$94.90
52W Low
$13.22
PE Ratio
-17.24
GPCR Fundamentals
Price
$62.90
Prev Close
$62.98
Open
$61.88
50D MA
$74.42
Beta
0.87
Avg. Volume
1.21M
EPS (Annual)
-$2.39
P/B
4.96
Rev/Employee
$0.00
$2,677.55
Loading...
Loading...
News
all
press releases
Structure Therapeutics (NASDAQ:GPCR) Stock Price Expected to Rise, HC Wainwright Analyst Says
HC Wainwright upped their price objective on Structure Therapeutics from $90.00 to $114.00 and gave the company a "buy" rating in a research note on Monday...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Structure Therapeutics Inc. Sponsored ADR $GPCR Shares Sold by Monashee Investment Management LLC
Monashee Investment Management LLC reduced its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 53.5% during the third quarter, according to the company in its...
MarketBeat·2d ago
News Placeholder
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded shares of Structure Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·3d ago
News Placeholder
Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $113.00 by Analysts at Citizens Jmp
Citizens Jmp reduced their price objective on shares of Structure Therapeutics from $120.00 to $113.00 and set a "market outperform" rating for the company in a research report on Friday...
MarketBeat·3d ago
News Placeholder
Structure Therapeutics (NASDAQ:GPCR) Releases Earnings Results, Beats Expectations By $999.35 EPS
Structure Therapeutics (NASDAQ:GPCR - Get Free Report) released its quarterly earnings data on Thursday. The company reported $999.00 earnings per share for the quarter, topping analysts' consensus...
MarketBeat·4d ago
News Placeholder
Private Capital Advisors Inc. Buys New Shares in Structure Therapeutics Inc. Sponsored ADR $GPCR
Private Capital Advisors Inc. acquired a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) during the 3rd quarter, according to its most recent filing with...
MarketBeat·4d ago
News Placeholder
Lilly's GLP-1 Blockbusters Drive 2025 Revenue Surge: What's Ahead?
LLY's Mounjaro and Zepbound drove 56% of revenues in 2025 as obesity demand surged, with new launches and Medicare access set to fuel growth.
Zacks·5d ago
News Placeholder
Lilly vs. Novo Nordisk: Obesity Drug Giants' Face-Off in 2026
LLY or NVO? With surging GLP-1 sales, oral obesity pills and diverging 2026 outlooks, the obesity drug race is entering a pivotal new phase.
Zacks·6d ago
News Placeholder
Aberdeen Group plc Boosts Stock Position in Structure Therapeutics Inc. Sponsored ADR $GPCR
Aberdeen Group plc increased its holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 46.1% during the 3rd quarter, according to its most recent Form 13F filing with...
MarketBeat·12d ago
News Placeholder
Can LLY's Next-Gen Obesity Pipeline Sustain Growth Amid Competition?
Lilly is advancing next-gen obesity drugs like oral orforglipron and retatrutide as competition heats up.
Zacks·13d ago
<
1
2
...
>

Latest GPCR News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.